Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PMN310 in Patients With Early Alzheimer's Disease

NCT06750432 is registered in ClinicalTrials.gov with ProMis Neurosciences, Inc as lead sponsor.

NCT NCT06750432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06750432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PMN310 in Patients With Early Alzheimer's Disease
Lead sponsor
ProMis Neurosciences, Inc
Phase
Phase 1
Overall status
Active, not recruiting
Start date
December 13, 2024
Completion date
December 31, 2026
Enrollment
144 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, early onset